GlassScriptPhysician profile
Mladen Solar
NPI 1780677823
$12,517.91
in general payments reported to CMS, 2019-2025
24 companies · $1,041 in 2025
The $1,041 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,482 · 2020: $1,210 · 2021: $2,798 · 2022: $1,772 · 2023: $1,892 · 2024: $1,323 · 2025: $1,041.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,068.96 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $2,807.06 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,856.20 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $1,022.52 | 2020-2025 | Nexletol |
| Pfizer INC. | $683.54 | 2019-2023 | |
| Glaxosmithkline, LLC. | $675.55 | 2019-2025 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $474.14 | 2019-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $372.67 | 2019-2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $251.46 | 2019-2020 | |
| Edwards Lifesciences Corporation | $231.76 | 2022-2025 | Sapien 3 Ultra Resilia |
| Novartis Pharmaceuticals Corporation | $146.61 | 2019-2023 | |
| Abbott Laboratories | $132.62 | 2022 | |
| Philips North America LLC | $132.56 | 2019 | |
| Amarin Pharma, INC. | $125.00 | 2019 | |
| Novo Nordisk INC | $125.00 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $125.00 | 2023 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $98.02 | 2020-2021 | |
| Inspire Medical Systems, INC. | $56.13 | 2024 | Inspire |
| Lilly USA, LLC | $34.44 | 2019-2020 | |
| Scpharmaceuticals INC. | $29.18 | 2025 | |
| Genentech USA, INC. | $19.73 | 2019 | |
| Exact Sciences Corporation | $17.79 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $17.72 | 2019 | |
| Abbvie INC. | $14.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mladen Solar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.